We offer a specialized service based on a unique human whole-blood loop assay, for detection of acute immune-related side effects of biopharmaceuticals (cytokine release), which provides a better understanding of first-in-man reactions prior to clinical trial entry. The assay platform can also be used to perform mode-of-action studies.
We are developing a new generation therapeutic peptide-based immuno-oncology vaccine powered by proprietary and patent-protected advanced TET technology that will enhance both peptide uptake and cellular immune activation. Our strategy is based on the delivery of our vaccine in an antigen-antibody immune complex formula. The primary focus is early stage, high-risk prostate cancer but the platform can be used for developing vaccines for other indications.
Are you interested in using our whole-blood loop model to assess toxicity or/and efficacy of your drug candidate? Contact us to find out how we can help you!
Are you interested in our patented TET-platform for development of cancer vaccines? Or would like to invest in the current project in the pipeline? Sign up to receive our latest news on drug development or investors’ information!
By invitation from Dagens Medicin Agenda Justyna Leja-Jarblad, Service Manager and Business Development at Immuneed held a pitch at Life Science Dagen on December 5.
Immuneed, a Swedish life science biotech company, today announced the publication of two key scientific publications, supporting both its immuno-service and its immuno-oncology offerings. The articles demonstrate Immuneed’s unique whole blood loop assay, a tool to predict first-infusion reactions of immunotherapeutics, and a novel targeting and adjuvant strategy to improve T cell responses that can be used for cancer vaccines.